FARICIMAB (Vabysmo) prior authorization at EmblemHealth
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
EmblemHealth requires prior-authorization documentation for FARICIMAB (Vabysmo): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
EmblemHealth reviews FARICIMAB (Vabysmo) prior authorizations against its medical policy . EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- EmblemHealth's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- HIP HMO referral denials
- GHI PPO out-of-network reductions (NYC municipal employee plan)
- Behavioral health prior auth
- Specialty drug PA
FARICIMAB (Vabysmo)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring aflibercept or bevacizumab first
- Quantity limit on injections per eye
- Off-label use beyond AMD/DME indication
Brand: Vabysmo. First bispecific antibody for retinal disease — targets both VEGF-A and Ang-2. FDA-approved for wet AMD, DME (2022), and macular edema following RVO (October 2023). Up to 16-week dosing intervals supported.
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when an EmblemHealth denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.emblemhealth.com/providers) with the same packet plus an applicable, current clinical source supporting FARICIMAB (Vabysmo)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an EmblemHealth denial on DenialHelp.
Contact EmblemHealth
- Provider portal: https://www.emblemhealth.com/providers
Frequently asked questions
What documentation does EmblemHealth need for FARICIMAB (Vabysmo) prior auth?
EmblemHealth's typical PA packet for FARICIMAB (Vabysmo): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at EmblemHealth?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for FARICIMAB (Vabysmo) at EmblemHealth?
Preparation scenarios to check against the current notice and policy include: HIP HMO referral denials; GHI PPO out-of-network reductions (NYC municipal employee plan); Behavioral health prior auth. These are not measured frequency claims. For FARICIMAB (Vabysmo), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with EmblemHealth on FARICIMAB (Vabysmo)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the FARICIMAB (Vabysmo) PA packet
Open ApprovalHelp — generate a FARICIMAB (Vabysmo) prior-auth packet tailored to EmblemHealth's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com